The U.S. government filed a civil lawsuit accusing Rochester Drug-Cooperative Inc., a large opioid distributor, of failing to report thousands of suspicious orders for controlled substances as part of a years-long drive to bolster profit.
Allergan reported in early March 2019 that an experimental adjunctive treatment for major depressive disorder failed to hit endpoints in a late-stage trial, however, a new study suggests rapastinel can benefit patients going through opioid withdrawal.
The one-time billionaire founder of Insys Therapeutics Inc. and four other former executives and managers of the opioid drugmaker will face trial over charges they conspired to pay doctors bribes to prescribe patients an addictive fentanyl spray to boost sales.
Members of the wealthy Sackler family behind Purdue Pharma LP pushed the company to boost sales of OxyContin and other opioids even as questions emerged about the extent the drugmaker’s painkillers were being abused, Massachusetts’ attorney general alleged.
The former chief executive of Insys Therapeutics Inc. agreed to plead guilty to participating in a scheme to bribe doctors.
Here are seven trends most likely to be hitting the news cycle in 2019 according to BioSpace.
The U.S. Food and Drug Administration’s Anesthetic and Analgesic Drug Products Advisory Committee voted to recommend AcelRx Pharmaceuticals’ Dsuvia to manage moderate-to-severe pain.
Trevena Inc.’s opioid injection to treat acute pain could be abused and potentially lead to overdose, staff reviewers of the U.S. FDA said, sending the drugmaker’s shares down 66 percent.
According to a drug shortage list provided by the U.S. Food and Drug Administration, there have been more than 100 drugs that have faced shortages during 2018.
Maryland charged Insys Therapeutics Inc. with deceptively marketing a powerful opioid pain killer so that it was prescribed inappropriately beyond its intended use with cancer patients.